Amicus Therapeutics, Inc. Stock London S.E.
Stocks
0HF9
US03152W1099
Biotechnology & Medical Research
| Market Cap | 4.55B 3.94B 3.68B 3.37B 6.34B 433B 6.44B 43.12B 16.92B 217B 17.09B 16.71B 718B | P/E 2024 |
-51.1x | P/E 2025 | -162x |
|---|---|---|---|---|---|
| Enterprise Value | 4.7B 4.06B 3.8B 3.48B 6.55B 447B 6.65B 44.53B 17.48B 224B 17.64B 17.26B 741B | EV / Sales 2024 |
5.69x | EV / Sales 2025 | 7.18x |
| Free-Float |
99.31% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Amicus Therapeutics, Inc.
| 1 day | +17.93% |
| Manager | Title | Age | Since |
|---|---|---|---|
George Davis
PSD | President | 55 | 27/04/2026 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +17.93% | +18.15% | - | - | 4.55B | |
| +0.99% | +1.78% | +5.07% | +16.49% | 49.47B | |
| +3.71% | +9.40% | +486.14% | +579.98% | 43.97B | |
| +5.60% | +10.21% | +20.85% | +81.78% | 39.6B | |
| +2.70% | +1.57% | +32.71% | +9.07% | 39.29B | |
| +2.21% | +6.75% | +20.20% | +54.40% | 32.43B | |
| +2.23% | +4.71% | - | - | 16.84B | |
| +0.97% | +2.35% | +35.99% | +124.45% | 16.49B | |
| -0.11% | +2.41% | +5.03% | +20.47% | 14.01B | |
| +0.75% | +15.04% | +79.84% | +29.70% | 12.77B | |
| Average | +3.70% | +6.32% | +85.73% | +114.54% | 29.43B | |
| Weighted average by Cap. | +2.80% | +6.10% | +105.13% | +138.67% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 528M 457M 427M 391M 736M 50.28B 748M 5.01B 1.97B 25.2B 1.98B 1.94B 83.31B | 634M 549M 512M 470M 884M 60.36B 898M 6.01B 2.36B 30.25B 2.38B 2.33B 100B |
| Net income | -56.11M -48.53M -45.32M -41.58M -78.2M -5.34B -79.44M -532M -209M -2.68B -211M -206M -8.85B | -27.11M -23.45M -21.9M -20.09M -37.78M -2.58B -38.39M -257M -101M -1.29B -102M -99.58M -4.28B |
| Net Debt | 194M 168M 156M 144M 270M 18.43B 274M 1.84B 721M 9.24B 727M 711M 30.55B | 149M 129M 120M 110M 207M 14.16B 211M 1.41B 554M 7.1B 559M 547M 23.47B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
